Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Computed tomography scans are widely used in everyday medical practice due to speed, image reliability, and detectability of a wide range of pathologies. Each scan exposes the patient to a radiation dose, and performing a fast estimation of the effective dose (E) is an important step for radiological safety. The aim of this work is to estimate E from patient and CT acquisition parameters in the absence of a dose-tracking software exploiting machine learning.

Methods: In total, 69,037 CT acquisitions were collected with the dose-tracking software (DTS) available at our institution. E calculated by DTS was chosen as the target value for prediction. Different machine learning algorithms were selected, optimizing parameters to achieve the best performance for each algorithm. Effective dose was also estimated using DLP and k-factors, and with multiple linear regression. Mean absolute error (MAE, mean absolute percentage error (MAPE), and R were used to evaluate predictions in the test set and in an external dataset of 3800 acquisitions.

Results: The random forest regressor (MAE: 0.416 mSv; MAPE: 7%; and R: 0.98) showed best performances over the neural network and the support vector machine. However, all three machine learning algorithms outperformed effective dose estimation using k-factors (MAE: 2.06; MAPE: 26%) or multiple linear regression (MAE: 0.98; MAPE: 44.4%). The random forest regressor on the external dataset showed an MAE of 0.215 mSv and an MAPE of 7.1%.

Conclusions: Our work demonstrated that machine learning models trained with data calculated by a dose-tracking software can provide good estimates of the effective dose just from patient and scanner parameters, without the need for a Monte Carlo approach.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11768726PMC
http://dx.doi.org/10.3390/tomography11010002DOI Listing

Publication Analysis

Top Keywords

effective dose
20
machine learning
16
dose-tracking software
12
dose estimation
8
computed tomography
8
learning algorithms
8
multiple linear
8
linear regression
8
external dataset
8
random forest
8

Similar Publications

Background: Stored-product insects (Sitophilus spp., Plodia interpunctella, Sitotroga cerealella) drive substantial postharvest losses and increasingly resist synthetic fumigants. Valeriana wallichii roots yield volatile oils rich in short-chain acids and sesquiterpenes.

View Article and Find Full Text PDF

The effect of non-functionalized polystyrene nanoparticles (PS-NPs) with diameters of 29, 44, and 72 nm on plasmid DNA integrity and the expression of genes involved in the architecture of chromatin was investigated in human peripheral blood mononuclear cells (PBMCs). The cells were incubated with PS-NPs at concentrations ranging from 0.001 to 100 µg/mL for 24 hours.

View Article and Find Full Text PDF

Purpose: To study the efficacy and safety of pro re nata regimen of brolucizumab, without loading dose, in treatment-naive patients with neovascular age-related macular degeneration (nAMD).

Case Series: Retrospective, observational study. We included all consecutive patients diagnosed with treatment- naïve nAMD undergoing Brolucizumab in Humanitas eye clinic, Turin, Italy between April 2022 and May 2023.

View Article and Find Full Text PDF

Background: Romosozumab is a sclerostin-inhibiting monoclonal antibody that is effective and safe for anabolic treatment in patients with osteoporosis. Its main adverse effects are local; the severity of these injection-site reactions in clinical trials was generally mild.

Case Report: We present a case of a 71-year-old Colombian woman with osteoporosis at very high risk of fractures with no relevant history of drug allergies.

View Article and Find Full Text PDF

Bietti crystalline dystrophy (BCD) is an autosomal recessive disorder caused by loss-of-function mutations in the gene, characterized by crystal-like lipid deposits in the retina, progressive photoreceptor loss, and retinal pigment epithelium (RPE) deterioration. Currently, there are no approved treatments for BCD. VGR-R01, an investigational gene therapy, uses subretinal administration of recombinant adeno-associated virus type 8 (AAV8) vector to deliver the human CYP4V2 gene.

View Article and Find Full Text PDF